Maxacalcitol (BioDeep_00000794526)
代谢物信息卡片
(5Z)-5-[(2E)-2-[1-[1-(3-hydroxy-3-methylbutoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
化学式: C26H42O4 (418.30829320000004)
中文名称: 马沙骨化醇
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)OCCC(C)(C)O
InChI: InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-
描述信息
D018977 - Micronutrients > D014815 - Vitamins > D004100 - Dihydroxycholecalciferols
D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols
D020011 - Protective Agents > D016588 - Anticarcinogenic Agents
D000970 - Antineoplastic Agents
D003879 - Dermatologic Agents
同义名列表
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:31801
- KEGGdrug: D01098
- PubChem: 6398761
- PubChem: 156619643
- PubChem: 12019456
- DrugBank: DB06272
- ChEMBL: CHEMBL333950
- CAS: 103909-75-7
- CAS: 132071-85-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mizuki Fukazawa-Shinotsuka, Tomohisa Saito, Masaichi Abe, Satofumi Iida, I-Ting Wang, Kimio Terao, Hsi-Hsien Chen, Ming-Che Liu. Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis.
Drug research.
2022 Jan; 72(1):23-33. doi:
10.1055/a-1581-7609. [PMID: 34488237] - Masayuki Tanemoto, Yoji Katsuoka. Conversion from intravenous maxacalcitol to oral vitamin D in secondary hyperparathyroidism management.
Clinical and experimental nephrology.
2022 01; 26(1):97-98. doi:
10.1007/s10157-021-02138-0. [PMID: 34549338] - Tetsuo Shoji, Shinya Nakatani, Daijiro Kabata, Katsuhito Mori, Ayumi Shintani, Hisako Yoshida, Kanae Takahashi, Keiko Ota, Hisako Fujii, Shinichiro Ueda, Shinichi Nishi, Tatsuya Nakatani, Minoru Yoshiyama, Kiyoshi Goto, Takayoshi Hamada, Masahito Imanishi, Eiji Ishimura, Sosuke Kagitani, Yoshikazu Kato, Yasuro Kumeda, Kiyoshi Maekawa, Takayasu Matsumura, Harumi Nagayama, Yasue Obi, Yoshiteru Ohno, Yoshinori Sai, Mayumi Sakurai, Satoshi Sasaki, Kaori Shidara, Shigeichi Shoji, Yoshihiro Tsujimoto, Kenjiro Yamakawa, Hideaki Yasuda, Shozo Yodoi, Masaaki Inaba, Masanori Emoto. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Clinical journal of the American Society of Nephrology : CJASN.
2021 04; 16(4):599-612. doi:
10.2215/cjn.16601020. [PMID: 33685864] - Kazunori Inoue, Isao Matsui, Takayuki Hamano, Keiji Okuda, Yasumasa Tsukamoto, Ayumi Matsumoto, Karin Shimada, Seiichi Yasuda, Yusuke Katsuma, Yoshitsugu Takabatake, Masaru Tanaka, Noriko Tanaka, Toshiaki Mano, Tetsuo Minamino, Yasushi Sakata, Yoshitaka Isaka. Maxacalcitol (22-Oxacalcitriol (OCT)) Retards Progression of Left Ventricular Hypertrophy with Renal Dysfunction Through Inhibition of Calcineurin-NFAT Activity.
Cardiovascular drugs and therapy.
2021 04; 35(2):381-397. doi:
10.1007/s10557-020-07111-9. [PMID: 33206298] - Shimaa Saad El-Din, Laila Rashed, Engy Medhat, Basma Emad Aboulhoda, Ahmed Desoky Badawy, Asmaa Mohammed ShamsEldeen, Marwa Abdelgwad. Active form of vitamin D analogue mitigates neurodegenerative changes in Alzheimer's disease in rats by targeting Keap1/Nrf2 and MAPK-38p/ERK signaling pathways.
Steroids.
2020 04; 156(?):108586. doi:
10.1016/j.steroids.2020.108586. [PMID: 31982424] - C-N Zhou, W Yao, Y-N Gong, Y Li, C-H Wang, Y-F Huo. 22-oxacalcitriol protects myocardial ischemia-reperfusion injury by suppressing NF-κB/TNF-α pathway.
European review for medical and pharmacological sciences.
2019 Jun; 23(12):5495-5502. doi:
10.26355/eurrev_201906_18219. [PMID: 31298403] - Magda Hamzawy, Sarah Ali Abdelhameed Gouda, Laila Rashed, Mary Attia Morcos, Heba Shoukry, Nivin Sharawy. 22-oxacalcitriol prevents acute kidney injury via inhibition of apoptosis and enhancement of autophagy.
Clinical and experimental nephrology.
2019 Jan; 23(1):43-55. doi:
10.1007/s10157-018-1614-y. [PMID: 29968126] - Chaohong Li, Songlou Yin, Hanqiu Yin, Lina Cao, Ting Zhang, Yong Wang. Efficacy and Safety of 22-Oxa-Calcitriol in Patients with Rheumatoid Arthritis: A Phase II Trial.
Medical science monitor : international medical journal of experimental and clinical research.
2018 Dec; 24(?):9127-9135. doi:
10.12659/msm.911628. [PMID: 30554233] - A Yajima, K Tsuchiya, L F Bonewald, M Inaba, Y Tominaga, T Tanizawa, A Ito, K Nitta. Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2018 05; 29(5):1203-1209. doi:
10.1007/s00198-018-4402-3. [PMID: 29492624] - Masaki Ohya, Mitsuru Yashiro, Tomohiro Sonou, Kouji Okuda, Kouichi Tatsuta, Toru Mima, Yoshinori Tone, Shigeo Negi, Yasushi Saika, Takashi Shigematsu. Intravenous Maxacalcitol Therapy Correlates with Serum Fibroblast Growth Factor 23 Levels in Hemodialysis Patients Independent of Serum Phosphate or Calcium Levels.
Contributions to nephrology.
2018; 196(?):44-51. doi:
10.1159/000485696. [PMID: 30041203] - Magda Hamzawy, Sarah Ali Abdelhameed Gouda, Laila Rashid, Mary Attia Morcos, Heba Shoukry, Nivin Sharawy. The cellular selection between apoptosis and autophagy: roles of vitamin D, glucose and immune response in diabetic nephropathy.
Endocrine.
2017 Oct; 58(1):66-80. doi:
10.1007/s12020-017-1402-6. [PMID: 28889337] - Kiichi Yamamoto, Moritoshi Iwagami, Takenori Seki, Shigeyuki Kano, Nobuo Ota, Manabu Ato. Dual antiplasmodial activity of vitamin D3 and its analog, 22-oxacalcitriol, by direct and indirect mechanisms.
Parasitology international.
2017 Apr; 66(2):89-99. doi:
10.1016/j.parint.2016.11.015. [PMID: 27919743] - Keitaro Yokoyama, Noriaki Kurita, Shingo Fukuma, Tadao Akizawa, Masafumi Fukagawa, Yoshihiro Onishi, Kiyoshi Kurokawa, Shunichi Fukuhara. Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2017 03; 32(3):534-541. doi:
10.1093/ndt/gfw020. [PMID: 26945054] - Kensuke Nakamura, Nobuo Tohyama, Masahiro Yamasaki, Hiroshi Ohta, Keitaro Morishita, Mitsuyoshi Takiguchi. Hypercalcemia in a Dog with Chronic Ingestion of Maxacalcitol Ointment.
Journal of the American Animal Hospital Association.
2016 Jul; 52(4):256-8. doi:
10.5326/jaaha-ms-6286. [PMID: 27259026] - Kumi Futawaka, Tetsuya Tagami, Yuki Fukuda, Rie Koyama, Ayaka Nushida, Shoko Nezu, Hironori Yamamoto, Miyuki Imamoto, Masato Kasahara, Kenji Moriyama. Transcriptional activation of the wild-type and mutant vitamin D receptors by vitamin D3 analogs.
Journal of molecular endocrinology.
2016 07; 57(1):23-32. doi:
10.1530/jme-16-0048. [PMID: 27154546] - Tadao Akizawa, Takashi Akiba, Hideki Hirakata, Eriko Kinugasa, Yoshihiro Tominaga, Masafumi Fukagawa, Keitaro Yokoyama, Wuyan Zhang, Peter G Linde, Masashi Suzuki. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2015 Jun; 19(3):225-34. doi:
10.1111/1744-9987.12242. [PMID: 25363733] - Shunsuke Goto, Hideki Fujii, Keiji Kono, Kentaro Nakai, Rie Awata, Yuriko Yonekura, Michinori Hirata, Masami Shinohara, Shinichi Nishi, Masafumi Fukagawa. 22-Oxacalcitriol attenuates bone loss in nonobese type 2 diabetes.
Bone.
2015 May; 74(?):153-9. doi:
10.1016/j.bone.2015.01.014. [PMID: 25645030] - Kyung Hwan Jeong, Katsuhiko Asanuma, Aida Lydia, Miyuki Takagi, Rin Asao, Fumiko Kodama, Etsuko Asanuma, Yasuhiko Tomino. Combination therapy with telmisartan and oxacalcitriol suppresses the progression of murine adriamycin nephropathy.
Nephron.
2015; 129(2):143-54. doi:
10.1159/000369346. [PMID: 25661164] - Kentaro Nakai, Hideki Fujii, Keiji Kono, Shunsuke Goto, Riko Kitazawa, Sohei Kitazawa, Michinori Hirata, Masami Shinohara, Masafumi Fukagawa, Shinichi Nishi. Vitamin D activates the Nrf2-Keap1 antioxidant pathway and ameliorates nephropathy in diabetic rats.
American journal of hypertension.
2014 Apr; 27(4):586-95. doi:
10.1093/ajh/hpt160. [PMID: 24025724] - Michinori Hirata, Ken-Ichi Serizawa, Ken Aizawa, Kenji Yogo, Yoshihito Tashiro, Satoshi Takeda, Yoshiyuki Moriguchi, Koichi Endo, Masafumi Fukagawa. 22-Oxacalcitriol prevents progression of endothelial dysfunction through antioxidative effects in rats with type 2 diabetes and early-stage nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2013 May; 28(5):1166-74. doi:
10.1093/ndt/gfs536. [PMID: 23239833] - Keiji Kono, Hideki Fujii, Kentaro Nakai, Shunsuke Goto, Riko Kitazawa, Sohei Kitazawa, Masami Shinohara, Michinori Hirata, Masafumi Fukagawa, Shinichi Nishi. Anti-oxidative effect of vitamin D analog on incipient vascular lesion in non-obese type 2 diabetic rats.
American journal of nephrology.
2013; 37(2):167-74. doi:
10.1159/000346808. [PMID: 23406697] - Tomoko Ikeuchi, Takashi Nakamura, Satoshi Fukumoto, Haruhiko Takada. A vitamin D3 analog augmented interleukin-8 production by human monocytic cells in response to various microbe-related synthetic ligands, especially NOD2 agonistic muramyldipeptide.
International immunopharmacology.
2013 Jan; 15(1):15-22. doi:
10.1016/j.intimp.2012.10.027. [PMID: 23159604] - Kazunori Inoue, Isao Matsui, Takayuki Hamano, Naohiko Fujii, Akihiro Shimomura, Chikako Nakano, Yasuo Kusunoki, Yoshitsugu Takabatake, Michinori Hirata, Akira Nishiyama, Yoshiharu Tsubakihara, Yoshitaka Isaka, Hiromi Rakugi. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3.
Laboratory investigation; a journal of technical methods and pathology.
2012 Dec; 92(12):1686-97. doi:
10.1038/labinvest.2012.107. [PMID: 22926646] - Yumie Aoshima, Masahide Mizobuchi, Hiroaki Ogata, Chiaki Kumata, Ai Nakazawa, Fumiko Kondo, Naoko Ono, Fumihiko Koiwa, Eriko Kinugasa, Tadao Akizawa. Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-α.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2012 May; 27(5):1800-6. doi:
10.1093/ndt/gfr758. [PMID: 22287655] - Aida Lydia, Katsuhiko Asanuma, Kanae Nonaka, Miyuki Takagi, Kyung-Hwan Jeong, Fumiko Kodama, Rin Asao, Etsuko Asanuma, Wiguno Prodjosudjadi, Yasuhiko Tomino. Effects of 22-oxa-calcitriol on podocyte injury in adriamycin-induced nephrosis.
American journal of nephrology.
2012; 35(1):58-68. doi:
10.1159/000334626. [PMID: 22189044] - M Adachi, T Miyoshi, N Shiraishi, H Shimada, S Sakaguchi, K Tomita, K Kitamura. A study of maintenance therapy after intravenous maxacalcitol for secondary hyperparathyroidism.
Clinical nephrology.
2011 Oct; 76(4):266-72. doi:
10.5414/cn106595. [PMID: 21955861] - Masanori Abe, Kazuyoshi Okada, Takashi Maruyama, Noriaki Maruyama, Masayoshi Soma, Koichi Matsumoto. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis.
Expert opinion on pharmacotherapy.
2010 Jul; 11(10):1611-20. doi:
10.1517/14656566.2010.495119. [PMID: 20540652] - Atsushi Saito, Yuji Matsumoto, Yuhta Oyama, Mitsuhiro Asaka, Hitoshi Yokoyama. Effectiveness of weekly percutaneous maxacalcitol injection therapy in patients with secondary hyperparathyroidism.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2010 Feb; 14(1):98-103. doi:
10.1111/j.1744-9987.2009.00706.x. [PMID: 20438525] - Kazuhiro Shiizaki, Ikuji Hatamura, Ikuo Imazeki, Yoshiyuki Moriguchi, Toshifumi Sakaguchi, Fumie Saji, Eiko Nakazawa, Shigeaki Kato, Tadao Akizawa, Eiji Kusano. Improvement of impaired calcium and skeletal homeostasis in vitamin D receptor knockout mice by a high dose of calcitriol and maxacalcitol.
Bone.
2009 Nov; 45(5):964-71. doi:
10.1016/j.bone.2009.07.013. [PMID: 19631778] - Isao Matsui, Takayuki Hamano, Kodo Tomida, Kazunori Inoue, Yoshitsugu Takabatake, Yasuyuki Nagasawa, Noritaka Kawada, Takahito Ito, Hiroshi Kawachi, Hiromi Rakugi, Enyu Imai, Yoshitaka Isaka. Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2009 Aug; 24(8):2354-61. doi:
10.1093/ndt/gfp117. [PMID: 19297354] - Ikuko Funatogawa, Takashi Funatogawa, Yasuo Ohashi. A bivariate autoregressive linear mixed effects model for the analysis of longitudinal data.
Statistics in medicine.
2008 Dec; 27(30):6367-78. doi:
10.1002/sim.3456. [PMID: 18825651] - Kazuhiro Shiizaki, Ikuji Hatamura, Eiko Nakazawa, Manabu Ogura, Takahiro Masuda, Tadao Akizawa, Eiji Kusano. Molecular and morphological approach of uremia-induced hyperplastic parathyroid gland following direct maxacalcitol injection.
Medical molecular morphology.
2008 Jun; 41(2):76-82. doi:
10.1007/s00795-008-0399-6. [PMID: 18592161] - Yoshihiro Tominaga, Susumu Matsuoka, Tetsuhiko Sato, Nobuyuki Uno, Norihiko Goto, Akio Katayama, Toshihito Haba. Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2007 Aug; 11(4):266-73. doi:
10.1111/j.1744-9987.2007.00489.x. [PMID: 17661832] - T Mochizuki, S Naganuma, Y Tanaka, Y Iwamoto, C Ishiguro, Y Kawashima, K Maekawa, A Suda, T Akiba. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study.
Clinical nephrology.
2007 Jan; 67(1):12-9. doi:
NULL. [PMID: 17269594] - Dennis Andress. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
Drugs.
2007; 67(14):1999-2012. doi:
10.2165/00003495-200767140-00003. [PMID: 17883284] - K Shiizaki, I Hatamura, S Negi, T Sakaguchi, F Saji, K Kunimoto, M Okamoto, I Imazeki, Y Muragaki, T Akizawa. Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism.
Kidney international.
2006 Aug; 70(3):486-95. doi:
10.1038/sj.ki.5001564. [PMID: 16788697] - K Shiizaki, S Negi, I Hatamura, K Tatsuta, M Shibata, S Shimada, T Sakaguchi, T Akizawa. Direct injection of calcitriol or its analog into hyperplastic parathyroid glands induces apoptosis of parathyroid cells.
Kidney international. Supplement.
2006 Jul; ?(102):S12-5. doi:
10.1038/sj.ki.5001596. [PMID: 16810304] - Motoko Tanaka, Kazuko Itoh, Kazunori Matsushita, Kazutaka Matsushita, Masafumi Fukagawa. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
Nephron. Clinical practice.
2006; 102(1):c1-7. doi:
10.1159/000088163. [PMID: 16166800] - Chieko Hamada, Kayo Hayashi, Ichiyu Shou, Masanori Inaba, Yuuki Ro, Hiroaki Io, Kunimi Maeda, Mitsumine Fukui, Yasuhiko Tomino. Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
2005 Nov; 25(6):570-5. doi:
10.1177/089686080502500613. [PMID: 16411524] - Shigeo Tamura, Kazue Ueki, Keiichi Mashimo, Yoshito Tsukada, Miyuki Naitoh, Yukiko Abe, Hironobu Kawai, Akiyasu Tsuchida, Ryoji Wakamatsu, Yoshihisa Nojima. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.
Clinical and experimental nephrology.
2005 Sep; 9(3):238-43. doi:
10.1007/s10157-005-0363-x. [PMID: 16189633] - Genichi Shimizu, Shinji Mitani, Shin Matsumoto, Akiko Kawakami, Kanji Nozaki, Hiroshi Naka, Yasuo Imanishi, Takami Miki, Masaaki Inaba, Yoshiki Nishizawa. [Acute response of serum PTH and bone markers after injection of 1alpha,25 (OH)2D3 and 22-oxacalcitrol in hemodialysis patient].
Clinical calcium.
2005 Sep; 15 Suppl 1(?):148-51; discussion 151. doi:
clica05s-1148151. [PMID: 16272648] - Yoshihiro Yamada, Masahiro Kumafuji, Takanori Sodeyama, Taichi Suzawa, Mitsuo Momose, Masuo Tokoo. [Suitable examination intervals for hemodialysis patients with secondary hyperparathyroidism treated with maxacalcitol].
Clinical calcium.
2005 Sep; 15 Suppl 1(?):144-7. doi:
clica05s-1144147. [PMID: 16272647] - Eiichi Chiba, Gotaro Sugawara. [Influence of serum phosphate level for effects of OCT pulse therapy in hyper-PTH HD patients].
Clinical calcium.
2005 Sep; 15 Suppl 1(?):113-5; discussion 115. doi:
clica05s-1113115. [PMID: 16272641] - Junichiro J Kazama, Hiroki Maruyama, Ichiei Narita, Fumitake Gejyo. Maxacalcitol is a possible less phosphatemic vitamin D analog.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2005 Aug; 9(4):352-4. doi:
10.1111/j.1744-9987.2005.00296.x. [PMID: 16076381] - J J Kazama, K Omori, N Takahashi, Y Ito, H Maruyama, I Narita, F Gejyo, Y Iwasaki, M Fukagawa. Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism.
Clinical nephrology.
2005 Jul; 64(1):64-8. doi:
10.5414/cnp64064. [PMID: 16047647] - Hayato Kaida, Masatoshi Ishibashi, Hidemi Nishida, Kenkichi Baba, Yuji Hiromatsu, Seiya Okuda, Naofumi Hayabuchi. Assessment of therapeutic effect in patients with secondary hyperparathyroidism using bone scintigraphy.
Annals of nuclear medicine.
2005 Jul; 19(5):367-72. doi:
10.1007/bf03027400. [PMID: 16164192] - Yuko Oyama, Junichiro James Kazama, Kentaro Omori, Noboru Higuchi, Shigemi Kameda, Suguru Yamamoto, Yumi Ito, Hiroki Maruyama, Ichiei Narita, Fumitake Gejyo. Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
Clinical and experimental nephrology.
2005 Jun; 9(2):142-7. doi:
10.1007/s10157-005-0342-2. [PMID: 15980949] - Ryoichi Ando, Shotaro Naito, Yuichro Inagaki, Toshihiko Hata, Yuji Ishida, Yoshiko Chida, Masayuki Takayama, Ken Tachibana, Masakazu Ohtsuka, Atsushi Inoue. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2005 Feb; 9(1):16-23. doi:
10.1111/j.1774-9987.2005.00216.x. [PMID: 15828901] - Kazuhiro Shiizaki, Shigeo Negi, Ikuji Hatamura, Toshifumi Sakaguchi, Fumie Saji, Ken Kunimoto, Masahide Mizobuchi, Ikuo Imazeki, Akira Ooshima, Tadao Akizawa. Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats.
Journal of the American Society of Nephrology : JASN.
2005 Jan; 16(1):97-108. doi:
10.1681/asn.2004030236. [PMID: 15574509] - Tadao Akizawa, Yasuo Ohashi, Takashi Akiba, Masashi Suzuki, Yoshiki Nishizawa, Etsuro Ogata, Eduardo Slatopolsky, Kiyoshi Kurokawa. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2004 Dec; 8(6):480-91. doi:
10.1111/j.1774-9987.2004.00191.x. [PMID: 15663548] - Izumi Yamamoto, Yoshimi Kawamura, Keita Hirano, Hiroshi Hayakawa, Takashi Shigematu. [Therapy for ROD and measurement of the bone mass].
Clinical calcium.
2004 Dec; 14(12):83-8. doi:
clica041218891894. [PMID: 15577179] - Shuichi Tsuruoka, Hisashi Yamamoto, Takashi Ioka, Hitoshi Ando, Tetsuo Saito, Akio Fujimura. Adsorption of oxacalcitriol by polysulphone haemodialyser in patients with secondary hyperparathyroidism.
British journal of clinical pharmacology.
2004 Nov; 58(5):488-95. doi:
10.1111/j.1365-2125.2004.02204.x. [PMID: 15521896] - Shigeru Yumita. [Advantage of intravenous pulse therapy with calcitriol or maxacalcitol in dialysis patients with renal hyperparathyroidism].
Clinical calcium.
2004 Sep; 14(9):69-72. doi:
clica040913691372. [PMID: 15577114] - Yoichiro Ikeda, Fumi Takemoto. [Serum calcium concentration and the safety of vitamin D therapy].
Clinical calcium.
2004 Sep; 14(9):79-82. doi:
clica040913791382. [PMID: 15577116] - Matsuhiko Hayashi, Yoshitsugu Tsuchiya, Yoshiaki Itaya, Tsuneo Takenaka, Kenji Kobayashi, Mamoru Yoshizawa, Ryuichi Nakamura, Toshiaki Monkawa, Atsuhiro Ichihara. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2004 Aug; 19(8):2067-73. doi:
10.1093/ndt/gfh329. [PMID: 15187195] - Shuichi Tsuruoka, Kenta Nishiki, Michi Wakaumi, Hisahi Yamamoto, Hitoshi Ando, Wang Ning, Akio Fujimura. Chronopharmacology of oxacalcitriol in 5/6 nephrectomized rats.
Life sciences.
2004 Jul; 75(7):809-22. doi:
10.1016/j.lfs.2004.01.020. [PMID: 15183074] - Kazutaka Murakami, Hiromi Miyachi, Asako Watanabe, Nahoko Kawamura, Mikiko Fujii, Shigehisa Koide, Masamitsu Murase, Hiroko Kushimoto, Midori Hasegawa, Makoto Tomita, Yoshiyuki Hiki, Satoshi Sugiyama. Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol.
Clinical and experimental nephrology.
2004 Jun; 8(2):134-8. doi:
10.1007/s10157-004-0283-1. [PMID: 15235930] - Michio Nakamura, Shohei Fuchinoue, Satoshi Teraoka. Avoidance of direct injury to the peripheral nerve with maxacalcitol (22oxa-1,25(OH)2D3) in rats.
Nephrology (Carlton, Vic.).
2004 Jun; 9(3):114-7. doi:
10.1111/j.1440-1797.2004.00250.x. [PMID: 15189170] - Naoko Miwa, Takashi Akiba. [The trend in the development of the active vitamin D3 and its analogues].
Nihon rinsho. Japanese journal of clinical medicine.
2004 May; 62 Suppl 5(?):364-7. doi:
NULL. [PMID: 15197946] - Junichiro J Kazama, Kentaro Omori, Noboru Higuchi, Naoki Takahashi, Yumi Ito, Hiroki Maruyama, Ichiei Narita, Thomas L Cantor, Ping Gao, Fumitake Gejyo. Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2004 Apr; 19(4):892-7. doi:
10.1093/ndt/gfh038. [PMID: 15031346] - Shuichi Tsuruoka, Michis Wakaumi, Hisashi Yamamoto, Akio Fujimura. Chronopharmacology of oxacalcitriol in rat model of osteoporosis.
European journal of pharmacology.
2004 Mar; 488(1-3):239-45. doi:
10.1016/j.ejphar.2004.02.007. [PMID: 15044057] - Tilman B Drüeke. Calcimimetics versus vitamin D: what are their relative roles?.
Blood purification.
2004; 22(1):38-43. doi:
10.1159/000074922. [PMID: 14732810] - Takashi Kihara, Haruo Ichikawa, Hisanori Morimoto, Ai Yano, Shigeru Akagi, Kazushi Nakao, Hiroko Kohmoto, Jun Wada, Isao Kumagai, Hirofumi Makino. Intravenous vitamin D therapy reduces PTH-(1-84)/large C fragments ratio in chronic hemodialysis patients.
Nephron. Clinical practice.
2004; 98(3):c93-100. doi:
10.1159/000080680. [PMID: 15528944] - Senji Okuno, Eiji Ishimura, Kayoko Kitatani, Hidenori Chou, Kyoko Nagasue, Kiyoshi Maekawa, Tsuyoshi Izumotani, Tomoyuki Yamakawa, Yasuo Imanishi, Tetsuo Shoji, Masaaki Inaba, Yoshiki Nishizawa. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2003 Dec; 18(12):2613-21. doi:
10.1093/ndt/gfg451. [PMID: 14605286] - Sawako Ohigashi, Ichiro Tatsuno, Daigaku Uchida, Mayumi Higurashi, Saori Hoshimoto, Naoto Seki, Natoake Hashimoto, Yasushi Saito. Topical treatment with 22-oxacalcitriol (OCT), a new vitamin D analogue, caused severe hypercalcemia with exacerbation of chronic renal failure in a psoriatic patient with diabetic nephropathy; a case report and analysis of the potential for hypercalcemia.
Internal medicine (Tokyo, Japan).
2003 Dec; 42(12):1202-5. doi:
10.2169/internalmedicine.42.1202. [PMID: 14714959] - J J Kazama, K Suzuki, A Yokoseki, A Oyanagi, S Goto, H Shimada, H Maruyama, I Narita, F Gejyo. Development of hungry bone syndrome after rapid lowering of PTH with intravenous maxacalcitol therapy in a patient with non-uremic secondary hyperparathyroidism.
Clinical nephrology.
2003 Nov; 60(5):369-71. doi:
10.5414/cnp60369. [PMID: 14640244] - Shigehiro Doi, Noriaki Yorioka, Koji Usui, Kenichiro Shigemoto, Satoru Harada. Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients.
Internal medicine (Tokyo, Japan).
2003 Oct; 42(10):955-9. doi:
10.2169/internalmedicine.42.955. [PMID: 14606707] - Kazuhiro Shiizaki, Ikuji Hatamura, Shigeo Negi, Nobuhiko Narukawa, Masahide Mizobuchi, Toshifumi Sakaguchi, Akira Ooshima, Tadao Akizawa. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia.
Kidney international.
2003 Sep; 64(3):992-1003. doi:
10.1046/j.1523-1755.2003.00154.x. [PMID: 12911549] - Michinori Hirata, Kyoko Katsumata, Koichi Endo, Naoshi Fukushima, Hiroyuki Ohkawa, Masafumi Fukagawa. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2003 Sep; 18(9):1770-6. doi:
10.1093/ndt/gfg296. [PMID: 12937223] - Fumihiko Koiwa, Takeshi Hasegawa, Ichiro Kojima, Terukuni Ideura. Time course of change in calcium x phosphorus product after percutaneous ethanol injection therapy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2003 Jun; 18 Suppl 3(?):iii53-7. doi:
10.1093/ndt/gfg1014. [PMID: 12771302] - D Brancaccio, M Cozzolino, A Galassi, A Bellasi, P Carpani, M Gallieni. [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
2003 May; 20 Suppl 22(?):S12-6. doi:
NULL. [PMID: 12851915] - Masako Yasuda, Takashi Akiba, Hiroshi Nihei. Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2003 Mar; 41(3 Suppl 1):S108-11. doi:
10.1053/ajkd.2003.50097. [PMID: 12612965] - Ikuo Imazeki. [Maxacalcitol, a medicine for secondary hyperparathyroidism (2 degrees HPT)].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica.
2003 Jan; 121(1):65-72. doi:
10.1254/fpj.121.65. [PMID: 12617040] - Toru Sanai, Masanori Tokumoto, Tadashi Hirano, Seiya Okuda. Different effects of 22-oxacalcitriol and calcitriol on the course of experimental chronic renal failure.
The Journal of laboratory and clinical medicine.
2002 Oct; 140(4):242-9. doi:
10.1067/mlc.2002.127371. [PMID: 12389022] - L Merida, M Shigetomi, K Ihara, T Tsubone, K Ikeda, A Yamaguchi, T Sugiyama, S Kawai. Effects of vitamin D analog, 22-oxa-1,25-dihydroxyvitamin D(3), on bone reconstruction by vascularized bone allograft.
Bone.
2002 Feb; 30(2):422-7. doi:
10.1016/s8756-3282(01)00680-9. [PMID: 11856652] - Alex J Brown, Adriana S Dusso, Eduardo Slatopolsky. Vitamin D analogues for secondary hyperparathyroidism.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2002; 17 Suppl 10(?):10-9. doi:
10.1093/ndt/17.suppl_10.10. [PMID: 12386264] - Jun Shiota, Araki Tanaka. [A case with secondary hyperparathyroidism suggesting the direct suppressive effect of maxacalcitol on osteoblasts].
Nihon Jinzo Gakkai shi.
2002; 44(5):471-5. doi:
NULL. [PMID: 12216480] - Fumiaki Takahashi, Tatsuya Furuichi, Keigo Yorozu, Setsu Kawata, Hidetomo Kitamura, Noboru Kubodera, Eduardo Slatopolsky. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2002; 17 Suppl 10(?):46-52. doi:
10.1093/ndt/17.suppl_10.46. [PMID: 12386269] - Nobuo Koike, Naohiko Hayakawa, Kazuo Tokuda, Kazuhiro Nishimiya, Kimitoshi Saito, Walter E Stumpf. In vivo time-course of receptor binding in the parathyroid gland of the vitamin D analogue [(3)H]1,25-dihydroxy-22-oxavitamin D(3) compared with [(3)H]1,25-dihydroxyvitamin D(3), determined by micro-autoradiography.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2002; 17 Suppl 10(?):53-7. doi:
10.1093/ndt/17.suppl_10.53. [PMID: 12386270] - Kenji Kasai, Ryouetsu Abe, Masanori Wakabayashi, Kazuyoshi Nakamura, Satoshi Sawatani, Tsunemichi Wakabayashi. [The clinical evaluation of maxacalcitol on therapy for secondary hyperparathyroidism of chronic hemodialysis patients].
Nihon Jinzo Gakkai shi.
2002; 44(5):464-70. doi:
NULL. [PMID: 12216479] - Eriko Kinugasa, Tadao Akizawa, Junko Takahashi, Kunihiro Nabeshima, Hiroaki Ogata, Fumiyoshi Nakayama, Terukuni Ideura. Effects of 1,25-dihydroxy-22-oxavitamin D(3) on parathyroid gland function in haemodialysis patients with secondary hyperparathyroidism.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2002; 17 Suppl 10(?):20-7. doi:
10.1093/ndt/17.suppl_10.20. [PMID: 12386265] - Tadao Akizawa, Masashi Suzuki, Takashi Akiba, Yoshiki Nishizawa, Yasuo Ohashi, Etsuro Ogata, Eduardo Slatopolsky, Kiyoshi Kurokawa. Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2002; 17 Suppl 10(?):28-36. doi:
10.1093/ndt/17.suppl_10.28. [PMID: 12386266] - Michinori Hirata, Koichi Endo, Kyoko Katsumata, Fumihiko Ichikawa, Noboru Kubodera, Masafumi Fukagawa. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2002; 17 Suppl 10(?):41-5. doi:
10.1093/ndt/17.suppl_10.41. [PMID: 12386268] - T Akizawa, M Suzuki, T Akiba, Y Nishizawa, K Kurokawa. Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2001 Oct; 38(4 Suppl 1):S147-51. doi:
10.1053/ajkd.2001.27425. [PMID: 11576942] - S Sugawara, S Yang, K Iki, J Hatakeyama, R Tamai, O Takeuchi, S Akashi, T Espevik, S Akira, H Takada. Monocytic cell activation by Nonendotoxic glycoprotein from Prevotella intermedia ATCC 25611 is mediated by toll-like receptor 2.
Infection and immunity.
2001 Aug; 69(8):4951-7. doi:
10.1128/iai.69.8.4951-4957.2001. [PMID: 11447173] - K Makibayashi, M Tatematsu, M Hirata, N Fukushima, K Kusano, S Ohashi, H Abe, K Kuze, A Fukatsu, T Kita, T Doi. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis.
The American journal of pathology.
2001 May; 158(5):1733-41. doi:
10.1016/s0002-9440(10)64129-6. [PMID: 11337371] - Y Tsukamoto, M Hanaoka, T Matsuo, T Saruta, M Nomura, Y Takahashi. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2000 Mar; 35(3):458-64. doi:
10.1016/s0272-6386(00)70198-3. [PMID: 10692271] - J Cunningham. What is the optimal regimen for vitamin D?.
Kidney international. Supplement.
1999 Dec; 73(?):S59-64. doi:
10.1046/j.1523-1755.1999.07307.x. [PMID: 10633466] - M Hirata, K Katsumata, T Masaki, N Koike, K Endo, K Tsunemi, H Ohkawa, K Kurokawa, M Fukagawa. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis.
Kidney international.
1999 Dec; 56(6):2040-7. doi:
10.1046/j.1523-1755.1999.00772.x. [PMID: 10594779] - A J Brown, E Slatopolsky. Vitamin D analogs: perspectives for treatment.
Mineral and electrolyte metabolism.
1999 Jul; 25(4-6):337-41. doi:
10.1159/000057470. [PMID: 10681662] - K Okano, T Usa, A Ohtsuru, T Tsukazaki, Y Miyazaki, A Yonekura, H Namba, H Shindoh, S Yamashita. Effect of 22-oxa-1,25-dihydroxyvitamin D3 on human thyroid cancer cell growth.
Endocrine journal.
1999 Apr; 46(2):243-52. doi:
10.1507/endocrj.46.243. [PMID: 10460008] - M C Monier-Faugere, Z Geng, R M Friedler, Q Qi, N Kubodera, E Slatopolsky, H H Malluche. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Kidney international.
1999 Mar; 55(3):821-32. doi:
10.1046/j.1523-1755.1999.055003821.x. [PMID: 10027919] - C W McIntyre, N J Schroeder, J M Burrin, J Cunningham. Effects of new analogues of vitamin D on bone cells: implications for treatment of uremic bone disease.
Kidney international.
1999 Feb; 55(2):500-11. doi:
10.1046/j.1523-1755.1999.00289.x. [PMID: 9987074] - N Koike, N Hayakawa, K Kumaki, W E Stumpf. In vivo dose-related receptor binding of the vitamin D analogue [3H]-1,25-dihydroxy-22-oxavitamin D3 (OCT) in rat parathyroid, kidney distal and proximal tubules, duodenum, and skin, studied by quantitative receptor autoradiography.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
1998 Dec; 46(12):1351-8. doi:
10.1177/002215549804601203. [PMID: 9815276] - M Ishigai, S Arai, Y Ishitani, K Kumaki. In vivo metabolism of the vitamin D analog, 22-oxacalcitriol: evidence for side-chain truncation and 17-hydroxylation.
The Journal of steroid biochemistry and molecular biology.
1998 Sep; 66(5-6):281-93. doi:
10.1016/s0960-0760(98)00061-2. [PMID: 9749834] - M Ishigai, Y Asoh, K Kumaki. Determination of 22-oxacalcitriol, a new analog of 1alpha,25-dihydroxyvitamin D3, in human serum by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications.
1998 Mar; 706(2):261-7. doi:
10.1016/s0378-4347(97)00553-7. [PMID: 9551812] - M Falzon, J Zong. The noncalcemic vitamin D analogs EB1089 and 22-oxacalcitriol suppress serum-induced parathyroid hormone-related peptide gene expression in a lung cancer cell line.
Endocrinology.
1998 Mar; 139(3):1046-53. doi:
10.1210/endo.139.3.5774. [PMID: 9492037] - H Funahashi, Y Tanaka, T Imai, M Wada, K Tsukamura, Y Hayakawa, N Matsuura, T Kikumori, M Oiwa, Y Tominaga, H Takagi. Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia.
Journal of endocrinological investigation.
1998 Jan; 21(1):43-7. doi:
10.1007/bf03347285. [PMID: 9633022] - T Furuichi, S Kawata, Y Asoh, K Kumaki, Y Ohyama. Differential time course of induction of 1alpha,25-dihydroxyvitamin D3-24-hydroxylase mRNA expression in rats by 1alpha,25-dihydroxyvitamin D3 and its analogs.
Life sciences.
1998; 62(5):453-9. doi:
10.1016/s0024-3205(97)01139-9. [PMID: 9449236]